AbCellera Biologics (ABCL) Net Income towards Common Stockholders (2020 - 2023)
AbCellera Biologics (ABCL) has disclosed Net Income towards Common Stockholders for 4 consecutive years, with -$47.2 million as the latest value for Q4 2023.
- For the quarter ending Q4 2023, Net Income towards Common Stockholders fell 57.73% year-over-year to -$47.2 million, compared with a TTM value of -$47.2 million through Sep 2024, up 63.49%, and an annual FY2024 reading of -$162.9 million, down 11.24% over the prior year.
- Net Income towards Common Stockholders was -$47.2 million for Q4 2023 at AbCellera Biologics, down from -$28.6 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $168.6 million in Q1 2022 and bottomed at -$47.2 million in Q4 2023.
- Average Net Income towards Common Stockholders over 4 years is $17.8 million, with a median of -$2.5 million recorded in 2020.
- Peak annual rise in Net Income towards Common Stockholders hit 5700.62% in 2021, while the deepest fall reached 693.91% in 2021.
- Year by year, Net Income towards Common Stockholders stood at $117.0 million in 2020, then plummeted by 48.76% to $59.9 million in 2021, then crashed by 149.87% to -$29.9 million in 2022, then tumbled by 57.73% to -$47.2 million in 2023.
- Business Quant data shows Net Income towards Common Stockholders for ABCL at -$47.2 million in Q4 2023, -$28.6 million in Q3 2023, and -$30.5 million in Q2 2023.